Trispecific T Cell Engagers Incorporating Conditional CD28 Co-stimulation (TriTCE Co-stim) to Improve Treatment Responses in Oncology
Trispecific T Cell Engagers Incorporating Conditional CD28 Co-stimulation (TriTCE Co-stim) to Improve Treatment Responses in Oncology
Azymetric Fc-based Therapeutic Modalities Enabling Tumor-Restricted Immune Cell Activation and Engagement
Azymetric Fc-based Therapeutic Modalities Enabling Tumor-Restricted Immune Cell Activation and Engagement
Screening Novel Format Antibodies to Design Bispecific ADCs that Address Target Heterogeneity
Screening Novel Format Antibodies to Design Bispecific ADCs that Address Target Heterogeneity
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve T cell function and antitumor responses in hard-to-treat cancers
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve T cell function and antitumor responses in hard-to-treat cancers
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Engineering and Preclinical Development of ZW171: A 2+1 Format Anti-MSLN T Cell Engager
Engineering and Preclinical Development of ZW171: A 2+1 Format Anti-MSLN T Cell Engager
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
Zymeworks Topoisomerase 1 Inhibitor ADC Platform: From Concept to Pipeline
